PCRX
Pacira BioSciences, Inc.NASDAQHealthcare$22.70-0.39%ClosedMarket Cap: $976.6M
As of 2026-04-06
Valuation
P/E (TTM)
138.84
PEG
1.30
P/B
1.39
P/S
1.34
EV/EBITDA
10.45
DCF Value
$676.05
FCF Yield
14.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.4%
Operating Margin
2.8%
Net Margin
1.0%
ROE
0.9%
ROA
0.8%
ROIC
0.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $196.9M | 72.3% | $3.2M | $1.6M | $0.04 | — |
| FY 2025 | $726.4M | 71.5% | $28.1M | $7.0M | $0.16 | — |
| Q3 2025 | $179.5M | 80.9% | $6.4M | $5.4M | $0.12 | — |
| Q2 2025 | $181.1M | 77.4% | $8.5M | $-4.8M | $-0.11 | — |
| Q1 2025 | $168.9M | 79.7% | $2.0M | $4.8M | $0.10 | — |
| Q4 2024 | $187.3M | 78.7% | $24.7M | $16.0M | $0.34 | — |
| FY 2024 | $701.0M | 75.7% | $-73.4M | $-99.6M | $-2.15 | — |
| Q3 2024 | $168.6M | 76.9% | $-139.5M | $-143.5M | $-3.11 | — |
| Q2 2024 | $178.0M | 75.1% | $28.2M | $18.9M | $0.39 | — |
| Q1 2024 | $167.1M | 71.6% | $13.2M | $9.0M | $0.19 | — |
| Q4 2023 | $181.2M | 73.7% | $33.2M | $24.9M | $0.48 | — |
| FY 2023 | $675.0M | 72.6% | $87.7M | $42.0M | $0.89 | — |